Background: Alopecia areata (AA) is an immune-mediated disease that targets anagen hair follicles. Despite various therapeutic options, there is no cure for AA. Prostaglandin analogues have been recognized as being capable of inducing hypertrichosis. Objective: To compare the efficacy and safety of bimatoprost to those of corticosteroid in the treatment of scalp AA. Methods: Thirty adult patients with patchy AA (S1) were included. Two AA patches were randomly assigned to treatment either by mometasone furoate 0.1% cream once daily (area A) or bimatoprost 0.03% solution twice daily (area B) for 3 months. Patients were assessed using the Severity of Alopecia Tool (SALT) scoring system for hair re-growth. Results: All responding AA patches showed significant reduction in their SALT score after therapy. Area B demonstrated significantly better results regarding rapidity of response in weeks, percentage of hair re-growth and side effects compared to area A. Conclusion: Bimatoprost solution represents a therapeutic option for scalp AA.

1.
Alkhalifah A, Alsantali A, Wang E, McElwee KJ, Shapiro J: Alopecia areata update. J Am Acad Dermatol 2010;62:191-202.
2.
Safavi KH, Muller SA, Suman VJ, Moshell AN, Melton LJ 3rd: Incidence of alopecia areata in Olmsted County, Minnesota, 1975 through 1989. Mayo Clin Proc 1995;70:628-633.
3.
Alkhalifah A: Topical and intralesional therapies for alopecia areata. Dermatol Ther 2011;24:355-363.
4.
Delamere FM, Sladden MJ, Dobbins HM, Leonardi-Bee J: Interventions for alopecia areata. Cochrane Database Syst Rev 2008;2: CD004413.
5.
Messenger AG, McKillop J, Farrant P, McDonagh AJ, Sladden M: British Association of Dermatologists' guidelines for the management of alopecia areata 2012. Br J Dermatol 2012;166:916-926.
6.
Johnstone MA: Hypertrichosis and increased pigmentation of eyelashes and adjacent hair in the region of the ipsilateral eyelids of patients treated with unilateral topical latanoprost. Am J Ophthalmol 1997;124:544-547.
7.
Wand M: Latanoprost and hyperpigmentation of eyelashes. Arch Ophthalmol 1997;115:1206-1208.
8.
Ochoa BE, Sah D, Wang G, Stamper R, Price VH: Instilled bimatoprost ophthalmic solution in patients with eyelash alopecia areata. J Am Acad Dermatol 2009;60:530-532.
9.
Roseborough I, Lee H, Chwalek J, Stamper R, Price VH: Lack of efficacy of topical latanoprost and bimatoprost ophthalmic solutions in promoting eyelash growth in patients with alopecia areata. J Am Acad Dermatol 2009;60:705-706.
10.
Faghihi G, Andalib F, Asilian A: The efficacy of latanoprost in the treatment of alopecia areata of eyelashes and eyebrows. Eur J Dermatol 2009;19:586-587.
11.
Coronel-Perez IM, Rodriguez-Rey EM, Camacho-Martinez FM: Latanoprost in the treatment of eyelash alopecia in alopecia areata universalis. J Eur Acad Dermatol Venereol 2010;24:481-485.
12.
Zaheri S, Hughes B: Successful use of bimatoprost in the treatment of alopecia of the eyelashes. Clin Exp Dermatol 2010;35:e161-e162.
13.
Olsen EA, Hordinsky MK, Price VH, Roberts JL, Shapiro J, Canfield D, Duvic M, King LE Jr, McMichael AJ, Randall VA, Turner ML, Sperling L, Whiting DA, Norris D; National Alopecia Areata Foundation: Alopecia areata investigational assessment guidelines - Part II. National Alopecia Areata Foundation. J Am Acad Dermatol 2004;51:440-447.
14.
Gilhar A, Etzioni A, Paus R: Alopecia areata. N Engl J Med 2012;366:1515-1525.
15.
Tosti A, Piraccini BM, Pazzaglia M, Vincenzi C: Clobetasol propionate 0.05% under occlusion in the treatment of alopecia totalis/universalis. J Am Acad Dermatol 2003;49:96-98.
16.
Khidhir KG, Woodward DF, Farjo NP, Farjo BK, Tang ES, Wang JW, Picksley SM, Randall VA: The prostamide-related glaucoma therapy, bimatoprost, offers a novel approach for treating scalp alopecias. FASEB J 2013;27:557-567.
17.
Thibaut S, De Becker E, Caisey L, Baras D, Karatas S, Jammayrac O, Pisella PJ, Bernard BA: Human eyelash characterization. Br J Dermatol 2010;162:304-310.
18.
Randall VA: Hormonal regulation of hair follicles exhibits a biological paradox. Semin Cell Dev Biol 2007;18:274-285.
19.
Li N, Chen XM, Zhou Y, Wei ML, Yao X: Travoprost compared with other prostaglandin analogues or timolol in patients with open-angle glaucoma or ocular hypertension: meta-analysis of randomized controlled trials. Clin Experiment Ophthalmol 2006;34:755-764.
20.
Cohen JL: Enhancing the growth of natural eyelashes: the mechanism of bimatoprost-induced eyelash growth. Dermatol Surg 2010;36:1361-1371.
21.
Vila TO, Camacho Martinez FM: Bimatoprost in the treatment of eyelash universalis alopecia areata. Int J Trichology 2010;2:86-88.
22.
Johnstone MA, Albert DM: Prostaglandin-induced hair growth. Surv Ophthalmol 2002;47(suppl 1):S185-S202.
23.
Gandolfi S, Simmons ST, Sturm R, Chen K, VanDenburgh AM; Bimatoprost Study Group 3: Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension. Adv Ther 2001;18:110-121.
24.
Law SK: Bimatoprost in the treatment of eyelash hypotrichosis. Clin Ophthalmol 2010;4:349-358.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.